Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
New data shows the combination of Akero’s efruxifermin and Ozempic can reduce liver fat, boosting both drugs’ prospects in NASH.
New data shows the combination of Akero’s efruxifermin and Ozempic can reduce liver fat, boosting both drugs’ prospects in NASH.